Edgewise Therapeutics, Inc.
EWTX
Classifica tra le azioni
#3975
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Prezzo delle azioni
$38.12
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$4.10B
Variazione (1 giorno)
2.50%
Variazione (1 anno)
147.69%
Paese
US
Scambia Edgewise Therapeutics, Inc. (EWTX)
Categoria
Healthcare
Rapporto P/B per Edgewise Therapeutics, Inc. (EWTX)
Rapporto P/B al October 2026 TTM: 8.90
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Edgewise Therapeutics, Inc., il rapporto P/B attuale (TTM) è 8.90. Alla fine del 2023, era pari a 2.19.
Storico del rapporto P/B per Edgewise Therapeutics, Inc. da 2019 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 8.90 | 65.65% |
| 2024 | 5.37 | 145.74% |
| 2023 | 2.19 | 58.22% |
| 2022 | 1.38 | -49.87% |
| 2021 | 2.76 | -106.24% |
| 2020 | -44.18 | -49.57% |
| 2019 | -87.61 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 6.251 | -29.73% |
US
|
|
| 13.2547 | 49.00% |
US
|
|
| 4.208 | -52.70% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -30.50% |
NL
|
